qa_id stringlengths 27 27 | qa_group_id stringlengths 28 32 | qa_family stringclasses 3
values | subtask_type stringclasses 7
values | qa_subtype stringclasses 3
values | cluster_id stringclasses 42
values | language stringclasses 1
value | split stringclasses 1
value | question stringlengths 148 1.41k | answer stringlengths 718 10.8k | claim_ids listlengths 0 8 | paper_ids listlengths 1 5 | evidence_span_ids listlengths 0 7 | association_ids listlengths 0 4 | hypothesis_ids listlengths 0 4 | record_json stringlengths 4.37k 33.7k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
QA:c0fdb6551eb60681a856013a | QAG:91d80dc3c6f927525a7dbdc7 | provenance_qa | exact_evidence_retrieval | provenance_qa | G001 | en | train | Which exact source passage supports the statement "We retrospectively analyzed clinical data of all patients with dMMR/MSI-H gastrointestinal malignancies who received preoperative PD1 blockade immunotherapy with or without chemotherapy in Ward 3, Gastrointestinal Cancer Center, Peking University Cancer Hospital from J... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:51a50671a940953da36c2235","quotes":["We retrospectively analyzed clinical data of all patients with dMMR/MSI-H ga... | [
"CLM:51a50671a940953da36c2235",
"CLM:030dc49284f8a34331af4784"
] | [
"PMCID:PMC9988634"
] | [
"SPAN:19d30dc9580b470ddf98fa6b"
] | [] | [] | {"qa_id":"QA:c0fdb6551eb60681a856013a","qa_group_id":"QAG:91d80dc3c6f927525a7dbdc7","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G001","question":"Which exact source passage supports the statement \"We retrospectively analyzed clinical data of all patients with dMM... |
QA:c145a472d2ba9656b2c6340e | QAG:a288e402369e36fd8eab17f4 | provenance_qa | exact_evidence_retrieval | provenance_qa | G001 | en | train | Which exact source passage supports the statement "Tumor microenvironment immune types in gastric cancer was associated with mismatch repair however, not HER2 status"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage wi... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:f2e5b0bedf0c2fa4e7d6771a","quotes":["Tumor microenvironment immune types in gastric cancer are associated with mi... | [
"CLM:f2e5b0bedf0c2fa4e7d6771a",
"CLM:00345af022967e4fba38c511"
] | [
"PMCID:PMC8941030"
] | [
"SPAN:80222f859dc5cb1aa8e4d805"
] | [] | [] | {"qa_id":"QA:c145a472d2ba9656b2c6340e","qa_group_id":"QAG:a288e402369e36fd8eab17f4","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G001","question":"Which exact source passage supports the statement \"Tumor microenvironment immune types in gastric cancer was associat... |
QA:c2c72bd021e90233b12f4fb4 | QAG:4773de660db66c4e6938653c | provenance_qa | exact_evidence_retrieval | provenance_qa | G001 | en | train | Which exact source passage supports the statement "In addition, 20 gastric cancer (GC) patients were enrolled as the second validation cohort"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim, and Evi... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:06d7a8039e910d5ad18fe47c","quotes":["In addition, 20 gastric cancer (GC) patients were recruited as the second va... | [
"CLM:06d7a8039e910d5ad18fe47c",
"CLM:00345af022967e4fba38c511"
] | [
"PMCID:PMC7430454"
] | [
"SPAN:ecbef4b429e394c402b9de36"
] | [] | [] | {"qa_id":"QA:c2c72bd021e90233b12f4fb4","qa_group_id":"QAG:4773de660db66c4e6938653c","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G001","question":"Which exact source passage supports the statement \"In addition, 20 gastric cancer (GC) patients were enrolled as the ... |
QA:c6ec35b0b27f194bb8dd6bd9 | QAG:b3a5de6cb15ca60a8f13fc9c | provenance_qa | exact_evidence_retrieval | provenance_qa | G001 | en | train | Which exact source passage supports the statement "(C) Boxplot showed an elevation in predicted neoantigens (NeoAgs) in ARID1A ‐loss gastric cancer (GC) tumors"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with pap... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:e2f5d019cd1336650292638b","quotes":["(C) Boxplot showed an elevation in predicted neoantigens (NeoAgs) in ARID1A ... | [
"CLM:e2f5d019cd1336650292638b",
"CLM:00345af022967e4fba38c511"
] | [
"PMCID:PMC10920992"
] | [
"SPAN:5851cad967e323cff31c5206"
] | [] | [] | {"qa_id":"QA:c6ec35b0b27f194bb8dd6bd9","qa_group_id":"QAG:b3a5de6cb15ca60a8f13fc9c","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G001","question":"Which exact source passage supports the statement \"(C) Boxplot showed an elevation in predicted neoantigens (NeoAgs) ... |
QA:cafb98beb125db257660099e | QAG:81086df89c3e42ac52a4cb8c | provenance_qa | exact_evidence_retrieval | provenance_qa | G001 | en | train | Which exact source passage supports the statement "It has also been reported that alpha‐E‐catenin 1 ( CTNNA1 ) pathogenic mutation was associated with HDGC"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:92ee6336816147e428d8e355","quotes":["It has also been reported that alpha‐E‐catenin 1 ( CTNNA1 ) pathogenic mutat... | [
"CLM:92ee6336816147e428d8e355",
"CLM:00345af022967e4fba38c511"
] | [
"PMCID:PMC10794017"
] | [
"SPAN:8c06475528a0635ac7791d6e",
"SPAN:ffcfb2e0c6f271e5ba1a538c"
] | [] | [] | {"qa_id":"QA:cafb98beb125db257660099e","qa_group_id":"QAG:81086df89c3e42ac52a4cb8c","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G001","question":"Which exact source passage supports the statement \"It has also been reported that alpha‐E‐catenin 1 ( CTNNA1 ) pathog... |
QA:cd16d439df4b69f36ae2ad4c | QAG:9a052872433fab51e58b342a | provenance_qa | exact_evidence_retrieval | provenance_qa | G001 | en | train | Which exact source passage supports the statement "16 months, 1 achieved PR and had an ORR of 33.3%"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim, and Evidence Span references; assess the embedded... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:154306489e4dec33809eb991","quotes":["Among the 3 gastric cancer patients who had received second‐line treatment, ... | [
"CLM:154306489e4dec33809eb991",
"CLM:00eb0bb1568a36713b5fdcb4"
] | [
"PMCID:PMC10794017"
] | [
"SPAN:71706d6a338d1092c3c1e72c"
] | [] | [] | {"qa_id":"QA:cd16d439df4b69f36ae2ad4c","qa_group_id":"QAG:9a052872433fab51e58b342a","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G001","question":"Which exact source passage supports the statement \"16 months, 1 achieved PR and had an ORR of 33.3%\"? Return the ori... |
QA:ce26bef1a0f706e213b2f4cb | QAG:400a1ca106e50fa18d3483b4 | provenance_qa | exact_evidence_retrieval | provenance_qa | G001 | en | train | Which exact source passage supports the statement "a Compared to the early T-stage, the advanced T-stage was associated with a higher stromal score (p < 0.001). b Distribution of stromal scores of GC subtypes"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requireme... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ab009a1e21bbf6869f9e875a","quotes":["Fig. 2 Stromal scores are associated with T-stage/overall survival/subtypes/... | [
"CLM:ab009a1e21bbf6869f9e875a",
"CLM:00eb0bb1568a36713b5fdcb4"
] | [
"PMCID:PMC7092673"
] | [
"SPAN:e4503540aa87bd8c5c1c4c5a"
] | [] | [] | {"qa_id":"QA:ce26bef1a0f706e213b2f4cb","qa_group_id":"QAG:400a1ca106e50fa18d3483b4","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G001","question":"Which exact source passage supports the statement \"a Compared to the early T-stage, the advanced T-stage was associat... |
QA:d3db2456251a8160c29d43d2 | QAG:38eddeda477c09abab561156 | provenance_qa | exact_evidence_retrieval | provenance_qa | G001 | en | train | Which exact source passage supports the statement "In a recent study, chemotherapy also demonstrated recruitment of CD8 + T cells and M1 macrophages in responders in the first-line treatment of advanced gastric cancer, but B cells, other than MDSC and T reg cells, were increased in non-responders 54"? Return the origin... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:8f907b4320d0f6f1d441f1e4","quotes":["In a recent study, chemotherapy also demonstrated recruitment of CD8 + T cel... | [
"CLM:8f907b4320d0f6f1d441f1e4",
"CLM:00eb0bb1568a36713b5fdcb4"
] | [
"PMCID:PMC9810618"
] | [
"SPAN:34ff1417a02105fc25d4357a"
] | [] | [] | {"qa_id":"QA:d3db2456251a8160c29d43d2","qa_group_id":"QAG:38eddeda477c09abab561156","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G001","question":"Which exact source passage supports the statement \"In a recent study, chemotherapy also demonstrated recruitment of C... |
QA:d68abb468c8be1bf551cb607 | QAG:ce7abde6f42234c7a68e467b | provenance_qa | exact_evidence_retrieval | provenance_qa | G001 | en | train | Which exact source passage supports the statement "FDA approved T‐DXd for use in advanced or metastatic HER2‐positive gastric or EGJ adenocarcinoma patients who had previously received trastuzumab‐based treatment. j Anti‐angiogenic drugs for advanced gastric cancer included ramucirumab (anti‐VEGFR2 monoclonal antibody)... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:133d490d6f96e27ddf2ea568","quotes":["In January 2021, the U.S. FDA approved T‐DXd for use in advanced or metastat... | [
"CLM:133d490d6f96e27ddf2ea568",
"CLM:030dc49284f8a34331af4784"
] | [
"PMCID:PMC10794017"
] | [
"SPAN:1ebc2e95e6cfc9d111af17d4"
] | [] | [] | {"qa_id":"QA:d68abb468c8be1bf551cb607","qa_group_id":"QAG:ce7abde6f42234c7a68e467b","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G001","question":"Which exact source passage supports the statement \"FDA approved T‐DXd for use in advanced or metastatic HER2‐positive... |
QA:d6fb6ccbd2c0875739174a6a | QAG:a9878ebce055614be76a53b2 | provenance_qa | paper_evidence_availability | provenance_qa | G001 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:37331333? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable an... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMID:37331333","verdict":"no_released_traceable_claim","reason":"No Cla... | [] | [
"PMID:37331333"
] | [] | [] | [] | {"qa_id":"QA:d6fb6ccbd2c0875739174a6a","qa_group_id":"QAG:a9878ebce055614be76a53b2","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G001","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:37331333? E... |
QA:d7a1bcf6708d593c16f695b1 | QAG:8b86380de98cc37f632a7bc4 | provenance_qa | exact_evidence_retrieval | provenance_qa | G001 | en | train | Which exact source passage supports the statement "k In the phase III clinical trial ORIENT‐16 , 650 patients with treatment naïve advanced gastric cancer were enrolled and the study compared sintilimab plus XELOX chemotherapy with a placebo plus XELOX chemotherapy"? Return the original wording with paper, Claim, and E... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:8bf19ff5c15d29e79ea130ee","quotes":["Apatinib was approved for third‐line or above treatment in patients with adv... | [
"CLM:8bf19ff5c15d29e79ea130ee",
"CLM:00eb0bb1568a36713b5fdcb4"
] | [
"PMCID:PMC10794017"
] | [
"SPAN:0fb6f64cb2f7bfed7f33eee0"
] | [] | [] | {"qa_id":"QA:d7a1bcf6708d593c16f695b1","qa_group_id":"QAG:8b86380de98cc37f632a7bc4","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G001","question":"Which exact source passage supports the statement \"k In the phase III clinical trial ORIENT‐16 , 650 patients with tr... |
QA:d840b37f2864cf2b8e0e3bd6 | QAG:d82bf90c2b6d84b4043bc2f3 | provenance_qa | exact_evidence_retrieval | provenance_qa | G001 | en | train | Which exact source passage supports the statement "The recent results of a Chinese randomized controlled study comparing the safety of LADG with D2 lymphadenectomy against open distal gastrectomy (ODG) with D2 lymphadenectomy in locally advanced gastric cancer (cT2‐4aN+M0) patients who received neoadjuvant chemotherapy... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:9f04d120e1749d787ebb4651","quotes":["The recent results of a Chinese randomized controlled study comparing the sa... | [
"CLM:9f04d120e1749d787ebb4651",
"CLM:00eb0bb1568a36713b5fdcb4"
] | [
"PMCID:PMC10794017"
] | [
"SPAN:d0f918ce5c04b9fc03d2eee0"
] | [] | [] | {"qa_id":"QA:d840b37f2864cf2b8e0e3bd6","qa_group_id":"QAG:d82bf90c2b6d84b4043bc2f3","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G001","question":"Which exact source passage supports the statement \"The recent results of a Chinese randomized controlled study compar... |
QA:d9cddf13300f53dceec5d5d0 | QAG:d66997f0f85aa166f8b11b1c | provenance_qa | exact_evidence_retrieval | provenance_qa | G001 | en | train | Which exact source passage supports the statement "This is probably because their role in the TME of gastric cancer may be less pronounced or the number of subjects enrolled led to a non-significant trend"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements:... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:7daef16f6faf9f550c074942","quotes":["This is probably because their role in the TME of gastric cancer may be less... | [
"CLM:7daef16f6faf9f550c074942",
"CLM:00eb0bb1568a36713b5fdcb4"
] | [
"PMCID:PMC9459198"
] | [
"SPAN:814e4ed4653948761a6ef13c"
] | [] | [] | {"qa_id":"QA:d9cddf13300f53dceec5d5d0","qa_group_id":"QAG:d66997f0f85aa166f8b11b1c","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G001","question":"Which exact source passage supports the statement \"This is probably because their role in the TME of gastric cancer m... |
QA:dbb29e192ab8f8a30b68227c | QAG:7d8bcc07d1f47e7ad63e2f9e | provenance_qa | paper_evidence_availability | provenance_qa | G001 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC6854775? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC6854775","verdict":"no_released_traceable_claim","reason":"No ... | [] | [
"PMCID:PMC6854775"
] | [] | [] | [] | {"qa_id":"QA:dbb29e192ab8f8a30b68227c","qa_group_id":"QAG:7d8bcc07d1f47e7ad63e2f9e","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G001","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC6854775... |
QA:dc436841bef98fd88e840cdb | QAG:98ba2f52c13e52e48ec336fb | provenance_qa | exact_evidence_retrieval | provenance_qa | G001 | en | train | Which exact source passage supports the statement "The recent results of a Chinese randomized controlled study comparing the safety of LADG with D2 lymphadenectomy against open distal gastrectomy (ODG) with D2 lymphadenectomy in locally advanced gastric cancer (cT2‐4aN+M0) patients who received neoadjuvant chemotherapy... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:9717a86419d4ffe9eeb82d55","quotes":["The recent results of a Chinese randomized controlled study comparing the sa... | [
"CLM:9717a86419d4ffe9eeb82d55",
"CLM:00eb0bb1568a36713b5fdcb4"
] | [
"PMCID:PMC10794017"
] | [
"SPAN:d0f918ce5c04b9fc03d2eee0"
] | [] | [] | {"qa_id":"QA:dc436841bef98fd88e840cdb","qa_group_id":"QAG:98ba2f52c13e52e48ec336fb","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G001","question":"Which exact source passage supports the statement \"The recent results of a Chinese randomized controlled study compar... |
QA:de84a46a6605e88ddfb4b0d1 | QAG:1a5d465f83b8c8b739bb33fa | provenance_qa | exact_evidence_retrieval | provenance_qa | G001 | en | train | Which exact source passage supports the statement "1 Among all genetic subclasses of gastric cancer, tumours with microsatellite instability (or mismatch repair deficiency) was associated with an improved response to immunotherapy"? Return the original wording with paper, Claim, and Evidence Span references.
Integrate... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:30979a8181ebf074c34ba389","quotes":["1 Among all genetic subclasses of gastric cancer, tumours with microsatellit... | [
"CLM:30979a8181ebf074c34ba389",
"CLM:020da5685d7d17cde8a85f67"
] | [
"PMCID:PMC8460994"
] | [
"SPAN:769e7d089a8c278d5960ab26"
] | [] | [] | {"qa_id":"QA:de84a46a6605e88ddfb4b0d1","qa_group_id":"QAG:1a5d465f83b8c8b739bb33fa","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G001","question":"Which exact source passage supports the statement \"1 Among all genetic subclasses of gastric cancer, tumours with mic... |
QA:e146be00f816e5036010ffcb | QAG:dad4d9cbe2fd40dac69629e3 | provenance_qa | exact_evidence_retrieval | provenance_qa | G001 | en | train | Which exact source passage supports the statement "3 Clinically, MMR deficient (dMMR)/MSI-high cancers was associated with particularly high response rates and durable benefit with immune checkpoint inhibitors (ICIs) and frontline use is supported by phase III evidence in metastatic colorectal cancer (mCRC)"? Return th... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:3f001575dc5ba7f2bd6df54b","quotes":["3 Clinically, MMR deficient (dMMR)/MSI-high cancers... | [
"CLM:3f001575dc5ba7f2bd6df54b",
"CLM:00eb0bb1568a36713b5fdcb4",
"CLM:f36d986959e3872159f9bc87"
] | [
"PMCID:PMC10255232",
"PMCID:PMC9988634"
] | [
"SPAN:0e6be7c879db295a68821686",
"SPAN:0b5ffb2bc4afa0d76766e287"
] | [
"ASC2:ffc05108ea43a984af809178"
] | [
"HYP:DCH:10d86b97af4b8c77741bcefd"
] | {"qa_id":"QA:e146be00f816e5036010ffcb","qa_group_id":"QAG:dad4d9cbe2fd40dac69629e3","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G001","question":"Which exact source passage supports the statement \"3 Clinically, MMR deficient (dMMR)/MSI-high cancers was associated... |
QA:e201b7780db7dccfd7314b43 | QAG:8b2e3a302f6b950807e9de34 | provenance_qa | exact_evidence_retrieval | provenance_qa | G001 | en | train | Which exact source passage supports the statement "For gastric cancer patients with T4b disease and without unresectable factors, based on current research evidence , the following points could be considered as treatment options: 1) R0 resection was a prognostic factor for survival; 2) the rate of complications after c... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:2dfa023052f74d8b5cb2b49f","quotes":["For gastric cancer patients with T4b disease and without unresectable factor... | [
"CLM:2dfa023052f74d8b5cb2b49f",
"CLM:00345af022967e4fba38c511"
] | [
"PMCID:PMC10794017"
] | [
"SPAN:4e6e4b2ccbe25341300853c2"
] | [] | [] | {"qa_id":"QA:e201b7780db7dccfd7314b43","qa_group_id":"QAG:8b2e3a302f6b950807e9de34","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G001","question":"Which exact source passage supports the statement \"For gastric cancer patients with T4b disease and without unresecta... |
QA:edb87c586832d57687bd6fde | QAG:a93ba257fc540178f0052790 | provenance_qa | exact_evidence_retrieval | provenance_qa | G001 | en | train | Which exact source passage supports the statement "The benefit of microsatellite instability is decreased by chemotherapy in stage II and stage III gastric cancer: Results from a large cohort with subgroup analyses"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance req... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:f36d986959e3872159f9bc87","quotes":["The benefit of microsatellite instability is attenuated by chemotherapy in s... | [
"CLM:f36d986959e3872159f9bc87",
"CLM:030dc49284f8a34331af4784"
] | [
"PMCID:PMC9988634"
] | [
"SPAN:0b5ffb2bc4afa0d76766e287"
] | [] | [] | {"qa_id":"QA:edb87c586832d57687bd6fde","qa_group_id":"QAG:a93ba257fc540178f0052790","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G001","question":"Which exact source passage supports the statement \"The benefit of microsatellite instability is decreased by chemothe... |
QA:edb8bf3a0aa8b93437d82ef6 | QAG:58c987f8160e537e74621bf2 | provenance_qa | exact_evidence_retrieval | provenance_qa | G001 | en | train | Which exact source passage supports the statement "reviewed the data of 1,464 pT3‐4 or N+ gastric cancer patients who received adjuvant fluoropyrimidine plus oxaliplatin (F‐OX) after D2 gastrectomy at three major centers across China"? Return the original wording with paper, Claim, and Evidence Span references.
Integr... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:9a962eb0e6fd4a2da6a984f5","quotes":["Wang et al. [ 87 ] reviewed the data of 1,464 pT3‐4 or N+ gastric cancer pat... | [
"CLM:9a962eb0e6fd4a2da6a984f5",
"CLM:020da5685d7d17cde8a85f67"
] | [
"PMCID:PMC10794017"
] | [
"SPAN:7a38e1d8dca5dffa02bb329c"
] | [] | [] | {"qa_id":"QA:edb8bf3a0aa8b93437d82ef6","qa_group_id":"QAG:58c987f8160e537e74621bf2","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G001","question":"Which exact source passage supports the statement \"reviewed the data of 1,464 pT3‐4 or N+ gastric cancer patients who... |
QA:ee09edf92beb89747bf06467 | QAG:079e8b5997bf04bddf19b65b | provenance_qa | exact_evidence_retrieval | provenance_qa | G001 | en | train | Which exact source passage supports the statement "This study aims to evaluate the efficacy and safety of preoperative PD-1 blockade immunotherapy in patients with dMMR/MSI-H locally advanced or metastatic gastrointestinal malignancies"? Return the original wording with paper, Claim, and Evidence Span references.
Inte... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:4008e6d923fed22b0792c822","quotes":["This study aimed to evaluate the efficacy and safety of preoperative PD-1 bl... | [
"CLM:4008e6d923fed22b0792c822",
"CLM:00eb0bb1568a36713b5fdcb4"
] | [
"PMCID:PMC9988634"
] | [
"SPAN:05262d9a848532c11dadbe18",
"SPAN:3c3ff17dabcadb323a410fec"
] | [] | [] | {"qa_id":"QA:ee09edf92beb89747bf06467","qa_group_id":"QAG:079e8b5997bf04bddf19b65b","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G001","question":"Which exact source passage supports the statement \"This study aims to evaluate the efficacy and safety of preoperativ... |
QA:ee473b4337eef946ba556812 | QAG:24db8c93ed066fcd5b66fcf8 | provenance_qa | exact_evidence_retrieval | provenance_qa | G001 | en | train | Which exact source passage supports the statement "CEA and CA19‐9) can effectively identify tumor recurrence as they may be increased 2‐3 months prior to evidence of tumor recurrence/metastasis detected by imaging examination . e For early gastric cancer with clinical cancer‐related anomalies, enhanced CT of the chest,... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:f1f546de7e20d778390df823","quotes":["For early gastric cancer patients who underwent radical resection, gastrosco... | [
"CLM:f1f546de7e20d778390df823",
"CLM:00eb0bb1568a36713b5fdcb4"
] | [
"PMCID:PMC10794017"
] | [
"SPAN:50e1aa6e07ab28d4c1c3cacf"
] | [] | [] | {"qa_id":"QA:ee473b4337eef946ba556812","qa_group_id":"QAG:24db8c93ed066fcd5b66fcf8","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G001","question":"Which exact source passage supports the statement \"CEA and CA19‐9) can effectively identify tumor recurrence as they ... |
QA:f2bd63275d21483cd6b8905e | QAG:1e751548e6e8739f203a0655 | provenance_qa | paper_evidence_availability | provenance_qa | G001 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC6492970? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC6492970","verdict":"no_released_traceable_claim","reason":"No ... | [] | [
"PMCID:PMC6492970"
] | [] | [] | [] | {"qa_id":"QA:f2bd63275d21483cd6b8905e","qa_group_id":"QAG:1e751548e6e8739f203a0655","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G001","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC6492970... |
QA:f498acf2200269be24cf04b9 | QAG:80e0e33c808d210b911dbec4 | provenance_qa | exact_evidence_retrieval | provenance_qa | G001 | en | train | Which exact source passage supports the statement "The cohort consisted of 248 patients diagnosed with gastric cancer who were hospitalized and received radical gastrectomy from 2007 to 2018 in the Department of Gastric and Colorectal Surgery in the First Hospital of Jilin University (Changchun, China)"? Return the ori... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:20ea2a9c19ea1472c0734ff0","quotes":["The cohort consisted of 248 patients diagnosed with gastric cancer who were ... | [
"CLM:20ea2a9c19ea1472c0734ff0",
"CLM:020da5685d7d17cde8a85f67"
] | [
"PMCID:PMC9514276"
] | [
"SPAN:bafcf1dcc40494a0b657813a"
] | [] | [] | {"qa_id":"QA:f498acf2200269be24cf04b9","qa_group_id":"QAG:80e0e33c808d210b911dbec4","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G001","question":"Which exact source passage supports the statement \"The cohort consisted of 248 patients diagnosed with gastric cancer... |
QA:f7698f2c46efff4e0da9af33 | QAG:8b81749f0107e802a338e1fd | provenance_qa | exact_evidence_retrieval | provenance_qa | G001 | en | train | Which exact source passage supports the statement "A 27-year-old female presenting with Stage IIIB (pT3N2aM0) CRC received surgery in August 2017 ( Fig. 3 )"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper,... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:9390e1abbc3eed464a5d0fc1","quotes":["A 27-year-old female presenting with Stage IIIB (pT3N2aM0) CRC received surg... | [
"CLM:9390e1abbc3eed464a5d0fc1",
"CLM:00345af022967e4fba38c511"
] | [
"PMCID:PMC10020813"
] | [
"SPAN:718dd31ba3428f69afd49c4d"
] | [] | [] | {"qa_id":"QA:f7698f2c46efff4e0da9af33","qa_group_id":"QAG:8b81749f0107e802a338e1fd","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G001","question":"Which exact source passage supports the statement \"A 27-year-old female presenting with Stage IIIB (pT3N2aM0) CRC rec... |
QA:f87bf783809ff3829786e8c0 | QAG:f533c1b5fe02b5a59a2494c4 | provenance_qa | paper_evidence_availability | provenance_qa | G001 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:32089413? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable an... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMID:32089413","verdict":"no_released_traceable_claim","reason":"No Cla... | [] | [
"PMID:32089413"
] | [] | [] | [] | {"qa_id":"QA:f87bf783809ff3829786e8c0","qa_group_id":"QAG:f533c1b5fe02b5a59a2494c4","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G001","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:32089413? E... |
QA:f9e624b7243ac9042fe4ca7d | QAG:3a3c57b2cb047fc23a9df2b8 | provenance_qa | exact_evidence_retrieval | provenance_qa | G001 | en | train | Which exact source passage supports the statement "Purpose The phase 3 ATTRACTION-2 study demonstrated that nivolumab monotherapy improved survival compared to placebo in patients with pretreated advanced gastric cancer (AGC)"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated pro... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:cbc23e09ab99abe5eff64b15","quotes":["Purpose The phase 3 ATTRACTION-2 study demonstrated that nivolumab monothera... | [
"CLM:cbc23e09ab99abe5eff64b15",
"CLM:00eb0bb1568a36713b5fdcb4"
] | [
"PMCID:PMC8994342"
] | [
"SPAN:2aff9809f4e101d3c2899861"
] | [] | [] | {"qa_id":"QA:f9e624b7243ac9042fe4ca7d","qa_group_id":"QAG:3a3c57b2cb047fc23a9df2b8","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G001","question":"Which exact source passage supports the statement \"Purpose The phase 3 ATTRACTION-2 study demonstrated that nivolumab... |
QA:fb79aca1dc156db613cd2323 | QAG:8db9a24097364b89e135882a | provenance_qa | paper_evidence_availability | provenance_qa | G001 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC10028156? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiabl... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC10028156","verdict":"no_released_traceable_claim","reason":"No... | [] | [
"PMCID:PMC10028156"
] | [] | [] | [] | {"qa_id":"QA:fb79aca1dc156db613cd2323","qa_group_id":"QAG:8db9a24097364b89e135882a","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G001","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC1002815... |
QA:fba65be2848bfeddeb87e754 | QAG:2e62e0ee3acf4cb83545e5c5 | provenance_qa | exact_evidence_retrieval | provenance_qa | G001 | en | train | Which exact source passage supports the statement "Eight of 16 patients with locally advanced colon cancer achieved pCR"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim, and Evidence Span references;... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:767ca00cd289b2ab70bab70b","quotes":["Eight of 16 patients with locally advanced colon cancer achieved pCR."],"cit... | [
"CLM:767ca00cd289b2ab70bab70b",
"CLM:030dc49284f8a34331af4784"
] | [
"PMCID:PMC9988634"
] | [
"SPAN:875bb633c95fd71f48d2d47b"
] | [] | [] | {"qa_id":"QA:fba65be2848bfeddeb87e754","qa_group_id":"QAG:2e62e0ee3acf4cb83545e5c5","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G001","question":"Which exact source passage supports the statement \"Eight of 16 patients with locally advanced colon cancer achieved p... |
QA:ff3745dce5cb69ffd4da4fa0 | QAG:6e480e598e41b2200e39a940 | provenance_qa | paper_evidence_availability | provenance_qa | G001 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:33846173? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable an... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMID:33846173","verdict":"no_released_traceable_claim","reason":"No Cla... | [] | [
"PMID:33846173"
] | [] | [] | [] | {"qa_id":"QA:ff3745dce5cb69ffd4da4fa0","qa_group_id":"QAG:6e480e598e41b2200e39a940","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G001","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:33846173? E... |
QA:ff44735dbd44a167fcc7fec1 | QAG:ca1bd2a8e95370a6999291bc | provenance_qa | exact_evidence_retrieval | provenance_qa | G001 | en | train | Which exact source passage supports the statement "cCR was achieved in seven of 36 cases, among which, six were selected for watch and wait strategy"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim, ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ff30895fa8d7cdcabfb9ed4c","quotes":["CR was achieved in four of five patients with low rectal cancer, including t... | [
"CLM:ff30895fa8d7cdcabfb9ed4c",
"CLM:00345af022967e4fba38c511"
] | [
"PMCID:PMC9988634"
] | [
"SPAN:74d64f9633803e6d666dc3d5"
] | [] | [] | {"qa_id":"QA:ff44735dbd44a167fcc7fec1","qa_group_id":"QAG:ca1bd2a8e95370a6999291bc","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G001","question":"Which exact source passage supports the statement \"cCR was achieved in seven of 36 cases, among which, six were selec... |
QA:03b58d4686ad56f29df21564 | QAG:9f484df049e510616ec1f632 | provenance_qa | paper_evidence_availability | provenance_qa | G002 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC8000490? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC8000490","verdict":"no_released_traceable_claim","reason":"No ... | [] | [
"PMCID:PMC8000490"
] | [] | [] | [] | {"qa_id":"QA:03b58d4686ad56f29df21564","qa_group_id":"QAG:9f484df049e510616ec1f632","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G002","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC8000490... |
QA:04c3f9f4f2a6927c671f1fff | QAG:eeb4eb374df3a3c720e0bfec | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "Other HER2-targeted agents, including pertuzumab, lapatinib, and ado-trastuzumab emtansine (T-DM1), have historically failed to meet benefits in patients with gastric cancer [ 10 – 12 ]"? Return the original wording with paper, Claim, and Evidence Span references.
Int... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:72fdec05b43916e51be37210","quotes":["Other HER2-targeted agents, including pertuzumab, l... | [
"CLM:72fdec05b43916e51be37210",
"CLM:0df5d18367ac7ad0c7f831b3",
"CLM:3124bcd31cd7ef9c603e2c35"
] | [
"PMCID:PMC10491560",
"PMCID:PMC8655175"
] | [
"SPAN:0db611bfc0e1679530fe6231",
"SPAN:47fae2c3ad825049b0c1ea8a"
] | [
"ASC2:8d9eb2f6893248137c6f12ad"
] | [
"HYP:DCH:d104b0e64777bae28bd9819a"
] | {"qa_id":"QA:04c3f9f4f2a6927c671f1fff","qa_group_id":"QAG:eeb4eb374df3a3c720e0bfec","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"Other HER2-targeted agents, including pertuzumab, lapatinib, and a... |
QA:062d547945b2e4bc6ec7cf66 | QAG:235f7cbc8e1734e5694709a6 | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "This review included pivotal clinical trial results and summarizes current clinical trials of HER2-directed therapy in gastric cancer"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact su... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:82e652474880f22f8945b933","quotes":["Areas covered This review discusses pivotal clinical trial results and summa... | [
"CLM:82e652474880f22f8945b933",
"CLM:0df5d18367ac7ad0c7f831b3"
] | [
"PMID:35034511"
] | [
"SPAN:6e154ad2d6d35fa88ed2d424"
] | [] | [] | {"qa_id":"QA:062d547945b2e4bc6ec7cf66","qa_group_id":"QAG:235f7cbc8e1734e5694709a6","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"This review included pivotal clinical trial results and summarizes... |
QA:090e62713b62dfd9b02fa5d2 | QAG:3793c68066e7212c5354c2c4 | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "Patients must have received trastuzumab in 1L on or after the mGC diagnosis"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim, and Evidence Span refe... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:91cd528560e3f64035280e3d","quotes":["Patients must have received trastuzumab in 1L on or after the mGC diagnosis.... | [
"CLM:91cd528560e3f64035280e3d",
"CLM:0df5d18367ac7ad0c7f831b3"
] | [
"PMCID:PMC10491560"
] | [
"SPAN:30f3cf0574e82dd0b0157204",
"SPAN:d1b4bb8fed032717fe462e33"
] | [] | [] | {"qa_id":"QA:090e62713b62dfd9b02fa5d2","qa_group_id":"QAG:3793c68066e7212c5354c2c4","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"Patients must have received trastuzumab in 1L on or after the mGC ... |
QA:0a9e2a947ad781ab11c6d30c | QAG:80b75ca76b348315b5ce6e8d | provenance_qa | paper_evidence_availability | provenance_qa | G002 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC9085816? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC9085816","verdict":"no_released_traceable_claim","reason":"No ... | [] | [
"PMCID:PMC9085816"
] | [] | [] | [] | {"qa_id":"QA:0a9e2a947ad781ab11c6d30c","qa_group_id":"QAG:80b75ca76b348315b5ce6e8d","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G002","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC9085816... |
QA:0aa744475d5595a46ec9a502 | QAG:2f7088f431eb76255900019a | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "Signature C of ERBB2 -Amp is similar to Signature 1, which was correlated with age and were found in all cancer types; while Signature B of ERBB2 -Amp is weakly correlated with other signatures (Figure S2A)"? Return the original wording with paper, Claim, and Evidence ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:4f2f384bfde2da1eb7e05634","quotes":["Compared with those 30 mutation signatures previously identified [ 40 ], Sig... | [
"CLM:4f2f384bfde2da1eb7e05634",
"CLM:0df5d18367ac7ad0c7f831b3"
] | [
"PMCID:PMC10405018"
] | [
"SPAN:29cd7e4f989d66957a3351fe"
] | [] | [] | {"qa_id":"QA:0aa744475d5595a46ec9a502","qa_group_id":"QAG:2f7088f431eb76255900019a","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"Signature C of ERBB2 -Amp is similar to Signature 1, which was cor... |
QA:0b4aceabb062b6b5c9633a4f | QAG:a8c6a7fafff91523a8f833b8 | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "In P1, adults with HER2+ breast or gastric cancer received PF-06804103 0.15–5.0 mg/kg intravenously once/21 days (Q3W); in P2, patients with HER2+ or HER2-low (IHC 1+ or IHC 2+/ISH−) breast cancer received 3.0 or 4.0 mg/kg Q3W"? Return the original wording with paper, ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:6ab23ef4aa52b534bc91d2b8","quotes":["In P1, adults with HER2+ breast or gastric cancer received PF-06804103 0.15–... | [
"CLM:6ab23ef4aa52b534bc91d2b8",
"CLM:0df5d18367ac7ad0c7f831b3"
] | [
"PMCID:PMC10543980"
] | [
"SPAN:2e65f32876a72173903d1e6b"
] | [] | [] | {"qa_id":"QA:0b4aceabb062b6b5c9633a4f","qa_group_id":"QAG:a8c6a7fafff91523a8f833b8","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"In P1, adults with HER2+ breast or gastric cancer received PF-0680... |
QA:0b7df18c5a72e41b3c2df383 | QAG:ad720a96971e5dcb491fdc92 | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "The scaffold protein IQGAP1 links heat‐ promoted stress signals to alternative splicing regulation in gastric cancer cells"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting pa... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:8a551b5332606f8b6dd29bac","quotes":["2009;583(12):1817–24. 51. Birladeanu AM, Rogalska M, Potiri M, Papadaki V, A... | [
"CLM:8a551b5332606f8b6dd29bac",
"CLM:0271f69b5949136c09787110"
] | [
"PMCID:PMC10397568"
] | [
"SPAN:e6981555b6f888a342edaf09"
] | [] | [] | {"qa_id":"QA:0b7df18c5a72e41b3c2df383","qa_group_id":"QAG:ad720a96971e5dcb491fdc92","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"The scaffold protein IQGAP1 links heat‐ promoted stress signals to... |
QA:1047eacff338c8b9dd44dae6 | QAG:99ae0b5dabcf016afbe69595 | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "For a decade, first-line Trastuzumab was the only licensed HER2-directed therapy for HER2 positive advanced gastric cancer following results from the ToGA trial in 2010 showed a survival benefit when added to chemotherapy"? Return the original wording with paper, Claim... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:d1aa7d8ff535f027cd24ef6f","quotes":["For a decade, first-line Trastuzumab was the only l... | [
"CLM:d1aa7d8ff535f027cd24ef6f",
"CLM:0df5d18367ac7ad0c7f831b3",
"CLM:7ed09b54db7cdf2c9858ef10",
"CLM:d1b34479a4fc86ef092eed94",
"CLM:1dbf11e43728bc11267262ca"
] | [
"PMID:35034511",
"PMCID:PMC9075004",
"PMCID:PMC9813086"
] | [
"SPAN:527919cc5e5909d732645233",
"SPAN:5f2f46d131f0253f25285a36",
"SPAN:a78ff7d9ac862e98905c06d6",
"SPAN:60f836fdb258a17cd895fecf"
] | [
"ASC2:9626c7142340534148f605b0",
"ASC2:a6f22b7200f3fbbb8fed7f00"
] | [
"HYP:DCH:e9fcbb609aabf723048a26f6"
] | {"qa_id":"QA:1047eacff338c8b9dd44dae6","qa_group_id":"QAG:99ae0b5dabcf016afbe69595","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"For a decade, first-line Trastuzumab was the only licensed HER2-di... |
QA:19a037577423af582ee1a185 | QAG:07688d7d3395597c6916a48f | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "Analysis based on The Cancer Genome Atlas data showed that GLS1 is highly expressed in various malignant tumors, such as gastric cancer, colorectal cancer, breast cancer, glioma, lung adenocarcinoma, and melanoma, and was associated with poor prognosis"? Return the ori... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:711f6a95444d659f317494c3","quotes":["Analysis based on The Cancer Genome Atlas data showed that GLS1 is highly ex... | [
"CLM:711f6a95444d659f317494c3",
"CLM:0271f69b5949136c09787110"
] | [
"PMCID:PMC10397568"
] | [
"SPAN:902def74d6277e2166d1e59e"
] | [] | [] | {"qa_id":"QA:19a037577423af582ee1a185","qa_group_id":"QAG:07688d7d3395597c6916a48f","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"Analysis based on The Cancer Genome Atlas data showed that GLS1 is... |
QA:1a26fc4cf55637d02720186f | QAG:05989cd990c78a6c84357361 | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "The patients included in this study were diagnosed with HER2‐positive gastric cancer and received trastuzumab treatment at Nanfang Hospital (Guangzhou, Guangdong, China) and Sun Yat‐sen University Cancer Center (Guangzhou, Guangdong, China) between 2013 and 2020. Immun... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:9245ef4cf43562a60d1f6a91","quotes":["2.1. The patients included in this study were diagnosed with HER2‐positive g... | [
"CLM:9245ef4cf43562a60d1f6a91",
"CLM:17f04cee2ef5778256edf078"
] | [
"PMCID:PMC10397568"
] | [
"SPAN:7f615dffd77bf7e5e7db9214"
] | [] | [] | {"qa_id":"QA:1a26fc4cf55637d02720186f","qa_group_id":"QAG:05989cd990c78a6c84357361","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"The patients included in this study were diagnosed with HER2‐posit... |
QA:1b680d813c5eee5fbbb4d252 | QAG:d7cf853d1257807070867060 | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "Combined treatment of duligotuzumab or ipatasertib and trastuzumab led to an important antiproliferative effect as compared to single agents all of HER2 gastric cancer cells ( Figure 1 A–F)"? Return the original wording with paper, Claim, and Evidence Span references.
... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:71d7660f18053d46e33eced8","quotes":["Combined treatment of duli... | [
"CLM:71d7660f18053d46e33eced8",
"CLM:0df5d18367ac7ad0c7f831b3",
"CLM:29b27485750fba0528103531",
"CLM:353ee387dc0c7fed5d59e3eb"
] | [
"PMCID:PMC8150287",
"PMCID:PMC10101806",
"PMCID:PMC10397568"
] | [
"SPAN:01135d9684d8ef085a58f659",
"SPAN:7dc91ac2bf94be3d2447ae6b",
"SPAN:457936dfbbc01d1ad0cba79b"
] | [
"ASC2:ee7f5ddfebfb7bdc88eb87b9",
"ASC2:5d67f17ae78a733c8c45e862"
] | [
"HYP:DCH:76cbcdfdefd2745034b86c63",
"HYP:DCH:c5ffb7bac915004c3a5761be"
] | {"qa_id":"QA:1b680d813c5eee5fbbb4d252","qa_group_id":"QAG:d7cf853d1257807070867060","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"Combined treatment of duligotuzumab or ipatasertib and trastuzumab... |
QA:1e23be2cb64912159e045e0a | QAG:651a30192f685a942129a9ba | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "CIPN, chemotherapy promoted peripheral neuropathy"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim, and Evidence Span references; assess the embedde... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:517536086fabdc234a17598e","quotes":["TABLE 3 Adverse Events in Patients With Advanced Gastric Cancer After Treatm... | [
"CLM:517536086fabdc234a17598e",
"CLM:0df5d18367ac7ad0c7f831b3"
] | [
"PMCID:PMC8781232"
] | [
"SPAN:9241eb424c178204e9866914"
] | [] | [] | {"qa_id":"QA:1e23be2cb64912159e045e0a","qa_group_id":"QAG:651a30192f685a942129a9ba","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"CIPN, chemotherapy promoted peripheral neuropathy\"? Return the or... |
QA:23bf522c4490e31656e6cc10 | QAG:b775e35291a5ad6d11d3b4bb | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "estimated a mean all-cause healthcare cost of US$16,242 per patient per month (PPPM) among patients with advanced or metastatic gastric cancer , and it was estimated the total national cost for hospitalizations with gastric cancer increased from US$1.79 billion in 2003... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:37850f6cce7aca25784f3488","quotes":["Abraham et al. estimated a mean all-cause healthcare cost of US$16,242 per p... | [
"CLM:37850f6cce7aca25784f3488",
"CLM:0271f69b5949136c09787110"
] | [
"PMCID:PMC10491560"
] | [
"SPAN:749821c6272d15b252c2a8bd"
] | [] | [] | {"qa_id":"QA:23bf522c4490e31656e6cc10","qa_group_id":"QAG:b775e35291a5ad6d11d3b4bb","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"estimated a mean all-cause healthcare cost of US$16,242 per patien... |
QA:2cba90219b4ad0997f0914fa | QAG:2e8ca7a23d130ecec64447d5 | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "The DESTINY-Gastric01 trial confirmed that therapy with trastuzumab deruxtecan led to significant improvements in response and overall survival among patients with HER2+ gastric cancer"? Return the original wording with paper, Claim, and Evidence Span references.
Inte... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:0271f69b5949136c09787110","quotes":["The DESTINY-Gastric01 trial confirmed that therapy ... | [
"CLM:0271f69b5949136c09787110",
"CLM:0df5d18367ac7ad0c7f831b3",
"CLM:1dbf11e43728bc11267262ca"
] | [
"PMCID:PMC10405018",
"PMCID:PMC9075004"
] | [
"SPAN:1f3d1ff76680e1d303eb53ff",
"SPAN:60f836fdb258a17cd895fecf"
] | [
"ASC2:df591f8c8e94aea8c814d709"
] | [
"HYP:DCH:c127f798bb9bcbbf3f8c5a5e"
] | {"qa_id":"QA:2cba90219b4ad0997f0914fa","qa_group_id":"QAG:2e8ca7a23d130ecec64447d5","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"The DESTINY-Gastric01 trial confirmed that therapy with trastuzuma... |
QA:2e0f075d2f54136e6059a48d | QAG:9d28dbe87f20418ea2a4396e | provenance_qa | paper_evidence_availability | provenance_qa | G002 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:31047804? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable an... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMID:31047804","verdict":"no_released_traceable_claim","reason":"No Cla... | [] | [
"PMID:31047804"
] | [] | [] | [] | {"qa_id":"QA:2e0f075d2f54136e6059a48d","qa_group_id":"QAG:9d28dbe87f20418ea2a4396e","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G002","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:31047804? E... |
QA:30f0bcb051b4b93d2509ea39 | QAG:e121f17b0f83e7a075253025 | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "This single-institution retrospective study evaluated 69 patients diagnosed with HER2-positive unresectable or metastatic gastric cancer who received T-DXd or nivolumab as third- or later-line treatments between March 2016 and May 2022 at the Cancer Institute Hospital ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:8f664e7e6d30292fe5785af8","quotes":["This single-institution retrospective study evaluated 69 patients diagnosed ... | [
"CLM:8f664e7e6d30292fe5785af8",
"CLM:0271f69b5949136c09787110"
] | [
"PMCID:PMC10630565"
] | [
"SPAN:40744af0124dbd5c08f5b40c"
] | [] | [] | {"qa_id":"QA:30f0bcb051b4b93d2509ea39","qa_group_id":"QAG:e121f17b0f83e7a075253025","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"This single-institution retrospective study evaluated 69 patients ... |
QA:341cd282d8bffaca69824c00 | QAG:da08ae2be439a7f5c64b4ca8 | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "Ninety-three patients enrolled in P1 ( n = 47: HER2+ gastric cancer = 22, HER2+ breast cancer = 25) and P2 [ n = 46: HER2+ breast cancer = 19, hormone receptor (HR)+ HER2-low breast cancer = 27] received PF-06804103. Four patients (3.0- and 4.0-mg/kg groups, n = 2 each... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:23ccaca1974a7804f62befd9","quotes":["Ninety-three patients enrolled in P1 ( n = 47: HER2+ gastric cancer = 22, HE... | [
"CLM:23ccaca1974a7804f62befd9",
"CLM:0df5d18367ac7ad0c7f831b3"
] | [
"PMCID:PMC10543980"
] | [
"SPAN:a8b7fdc1dc3e9ed2bb18a9a1"
] | [] | [] | {"qa_id":"QA:341cd282d8bffaca69824c00","qa_group_id":"QAG:da08ae2be439a7f5c64b4ca8","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"Ninety-three patients enrolled in P1 ( n = 47: HER2+ gastric cance... |
QA:3968f712e641da9c55820e64 | QAG:8a3446a0f0c33b41b33d4f2b | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "Background Multiple mechanisms have been proposed that lead to decreased effectiveness of trastuzumab in HER2-positive gastric cancer (GC), yet resistance to trastuzumab remains a challenge in clinics"? Return the original wording with paper, Claim, and Evidence Span r... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:52ce793834680a7e9a0f558c","quotes":["Background Multiple mechanisms have been proposed t... | [
"CLM:52ce793834680a7e9a0f558c",
"CLM:0df5d18367ac7ad0c7f831b3",
"CLM:9e22fa55f74f75b6800cb01c"
] | [
"PMCID:PMC9427959",
"PMCID:PMC9556512"
] | [
"SPAN:894c660b4595cfc94de82aa3",
"SPAN:95b8166a5505218c05fd6d63"
] | [
"ASC2:625cd8b990c8355a0f178692"
] | [
"HYP:DCH:42d0a32e04deb005d4916a3c"
] | {"qa_id":"QA:3968f712e641da9c55820e64","qa_group_id":"QAG:8a3446a0f0c33b41b33d4f2b","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"Background Multiple mechanisms have been proposed that lead to dec... |
QA:3e9bb08cad5bc92ba7da381c | QAG:473f954aad3962f07abf6955 | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "gov : NCT03185988 ) aims to evaluate the antitumor activity of trastuzumab and chemotherapy in HER2-positive digestive cancers excluding gastric cancer in 2017. Patients from this trial with HER2-positive, KRAS / BRAF wild-type, unresectable mCRC were analyzed in this ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:5d1b30abe9b70b562ab63e93","quotes":["Materials and Methods An open-label, phase II trial... | [
"CLM:5d1b30abe9b70b562ab63e93",
"CLM:0df5d18367ac7ad0c7f831b3",
"CLM:8a761323f291c5d518132388"
] | [
"PMCID:PMC10101806",
"PMCID:PMC10730520"
] | [
"SPAN:64aba72ce3b62600b2dd45b3",
"SPAN:7e124c040720954c924c584d"
] | [
"ASC2:29fd58816f6fe5f4aa6a45c0"
] | [
"HYP:DCH:8e5558ee63f43fbee27fdd0e"
] | {"qa_id":"QA:3e9bb08cad5bc92ba7da381c","qa_group_id":"QAG:473f954aad3962f07abf6955","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"gov : NCT03185988 ) aims to evaluate the antitumor activity of tra... |
QA:4bcb7531bef0b3a3cb7ede0f | QAG:4dbc77c0f736e8adb99cb1f5 | provenance_qa | paper_evidence_availability | provenance_qa | G002 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC11298287? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiabl... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC11298287","verdict":"no_released_traceable_claim","reason":"No... | [] | [
"PMCID:PMC11298287"
] | [] | [] | [] | {"qa_id":"QA:4bcb7531bef0b3a3cb7ede0f","qa_group_id":"QAG:4dbc77c0f736e8adb99cb1f5","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G002","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC1129828... |
QA:4ca94659b6ef47a4a7ce31e0 | QAG:336eba39331d1069ad80d7c3 | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "Abstract Gastric cancer is a prevalent malignancy with a high degree of heterogeneity, which has led to a poor therapeutic response"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supp... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:6e79f863971851f967f598a6","quotes":["Abstract Gastric cancer is a prevalent malignancy with a high degree of hete... | [
"CLM:6e79f863971851f967f598a6",
"CLM:0df5d18367ac7ad0c7f831b3"
] | [
"PMCID:PMC10405018"
] | [
"SPAN:1c29d4ed34573a93b2d7de99"
] | [] | [] | {"qa_id":"QA:4ca94659b6ef47a4a7ce31e0","qa_group_id":"QAG:336eba39331d1069ad80d7c3","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"Abstract Gastric cancer is a prevalent malignancy with a high degr... |
QA:5024d871bd81cdfa2930abfd | QAG:a8fb91b1229a5e243d1b79a2 | provenance_qa | paper_evidence_availability | provenance_qa | G002 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC10586480? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiabl... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC10586480","verdict":"no_released_traceable_claim","reason":"No... | [] | [
"PMCID:PMC10586480"
] | [] | [] | [] | {"qa_id":"QA:5024d871bd81cdfa2930abfd","qa_group_id":"QAG:a8fb91b1229a5e243d1b79a2","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G002","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC1058648... |
QA:54c758173d19c804dd863139 | QAG:7c1802253466dabe12d682a7 | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "Moreover, HER2 is overexpressed and amplified in ≈20% of gastric cancer (GC) patients, where it was associated with a poor prognosis and is currently recognized as a new diagnostic factor and novel therapeutic target. Accordingly, HER2 is recognized as the first target... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:3124bcd31cd7ef9c603e2c35","quotes":["Moreover, HER2 is overexpressed and amplified in ≈2... | [
"CLM:3124bcd31cd7ef9c603e2c35",
"CLM:0df5d18367ac7ad0c7f831b3",
"CLM:0271f69b5949136c09787110"
] | [
"PMCID:PMC8655175",
"PMCID:PMC10405018"
] | [
"SPAN:47fae2c3ad825049b0c1ea8a",
"SPAN:1f3d1ff76680e1d303eb53ff"
] | [
"ASC2:a04b41d3be4792b67b38dbbd"
] | [
"HYP:DCH:4ce7e56b5158f0074baf0662"
] | {"qa_id":"QA:54c758173d19c804dd863139","qa_group_id":"QAG:7c1802253466dabe12d682a7","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"Moreover, HER2 is overexpressed and amplified in ≈20% of gastric c... |
QA:5a53d5a4c33186fa42d94227 | QAG:1cddd1941fe86324028b8584 | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "Methods Patients with human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer who were previously treated with trastuzumab received trastuzumab every 3 weeks and irinotecan every 2 weeks"? Return the original wording with paper, Claim, and Evid... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:1dbf11e43728bc11267262ca","quotes":["Methods Patients with human epidermal growth factor... | [
"CLM:1dbf11e43728bc11267262ca",
"CLM:17f04cee2ef5778256edf078",
"CLM:0271f69b5949136c09787110",
"CLM:d1aa7d8ff535f027cd24ef6f"
] | [
"PMCID:PMC9075004",
"PMCID:PMC10405018",
"PMID:35034511"
] | [
"SPAN:60f836fdb258a17cd895fecf",
"SPAN:1f3d1ff76680e1d303eb53ff",
"SPAN:527919cc5e5909d732645233"
] | [
"ASC2:df591f8c8e94aea8c814d709",
"ASC2:a6f22b7200f3fbbb8fed7f00"
] | [
"HYP:DCH:fa99667be03c0bc5ff5da205"
] | {"qa_id":"QA:5a53d5a4c33186fa42d94227","qa_group_id":"QAG:1cddd1941fe86324028b8584","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"Methods Patients with human epidermal growth factor receptor 2 (HE... |
QA:5e82a16a2c8b084fda052de3 | QAG:f5282633a68166d7af366d5f | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "Overall, T-DXd was predicted to have meaningful clinical activity and a manageable safety profile in Western patients with HER2-positive gastric cancer"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: r... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:5ad7e8cffc6f4d0f53cd671f","quotes":["Overall, T-DXd was predicted to have meaningful clinical activity and a mana... | [
"CLM:5ad7e8cffc6f4d0f53cd671f",
"CLM:17f04cee2ef5778256edf078"
] | [
"PMID:37377133"
] | [
"SPAN:473732d87a7ab38bfeeba313"
] | [] | [] | {"qa_id":"QA:5e82a16a2c8b084fda052de3","qa_group_id":"QAG:f5282633a68166d7af366d5f","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"Overall, T-DXd was predicted to have meaningful clinical activity ... |
QA:5ffdc2238953bdf2613a4780 | QAG:e03abdb16eee545e033045d1 | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "The addition of trastuzumab to chemotherapy improved survival in patients with chemotherapy-naïve advanced gastric- or gastroesophageal junction cancer compared with the efficacy of chemotherapy alone in the ToGA study"? Return the original wording with paper, Claim, a... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:4ce84ca405dff38c243f614e","quotes":["The addition of trastuzumab to chemotherapy improved survival in patients wi... | [
"CLM:4ce84ca405dff38c243f614e",
"CLM:0df5d18367ac7ad0c7f831b3"
] | [
"PMCID:PMC9075004"
] | [
"SPAN:ad209745b97cfae39115e368"
] | [] | [] | {"qa_id":"QA:5ffdc2238953bdf2613a4780","qa_group_id":"QAG:e03abdb16eee545e033045d1","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"The addition of trastuzumab to chemotherapy improved survival in p... |
QA:67f28c5d798b58b49cec186b | QAG:d1c919396aa37aa1d3f4c334 | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "JACOB’s end-of study analyses aims to evaluate the long-term efficacy and safety of pertuzumab plus trastuzumab and chemotherapy for previously untreated HER2-positive metastatic gastric or gastroesophageal junction cancer"? Return the original wording with paper, Clai... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:43cde8df325291a4af2574ba","quotes":["JACOB’s end-of study analy... | [
"CLM:43cde8df325291a4af2574ba",
"CLM:0df5d18367ac7ad0c7f831b3",
"CLM:486fc53f92f4bf183a099282",
"CLM:5d50a3c09d9f0837bb9e0898",
"CLM:49f1edbd551f98416196817e",
"CLM:2117bab5d89c921d5d76db93"
] | [
"PMCID:PMC9813086",
"PMCID:PMC9398097",
"PMID:37377133",
"PMCID:PMC9662874"
] | [
"SPAN:a0c8a381518c85cb2105251c",
"SPAN:a7ffaf138d98a080bde2adaf",
"SPAN:a61cb9349f7cf5bccf8174d3",
"SPAN:e3efb99988d24d03093bb010",
"SPAN:a66c620f797193955a04eeb1"
] | [
"ASC2:1e75e299392604f63943fe85",
"ASC2:22c104957c4e5b73ce0318e0",
"ASC2:836a093bcf9f8fc0f8ee1e59"
] | [
"HYP:DCH:03c3ec249fa0faee61d38caa"
] | {"qa_id":"QA:67f28c5d798b58b49cec186b","qa_group_id":"QAG:d1c919396aa37aa1d3f4c334","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"JACOB’s end-of study analyses aims to evaluate the long-term effic... |
QA:69f6fdfa66c153f2b7b3eaf8 | QAG:b6b59526c6fa87edcf0b4590 | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "For instance, studies have reported that overexpression of BMAL1 increased the sensitivity of paclitaxel in tongue squamous cell carcinoma and the sensitivity of oxaliplatin and bevacizumab in colorectal cancer ( 40–42 )"? Return the original wording with paper, Claim,... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:17f04cee2ef5778256edf078","quotes":["For instance, studies have reported that overexpression of BMAL1 increased t... | [
"CLM:17f04cee2ef5778256edf078",
"CLM:0271f69b5949136c09787110"
] | [
"PMCID:PMC9662874"
] | [
"SPAN:9bc75f361a4687893b5f8557"
] | [] | [] | {"qa_id":"QA:69f6fdfa66c153f2b7b3eaf8","qa_group_id":"QAG:b6b59526c6fa87edcf0b4590","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"For instance, studies have reported that overexpression of BMAL1 i... |
QA:6e5e23205010ae128840fffd | QAG:267a6a1c9e2bed782d187a03 | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "Although the use of last generation chemotherapy regimens has improved survival in patients with gastric cancer, the prognosis of unresectable or metastatic gastric cancer patients remains poor, with a median overall survival of 12 months and a 5-year survival < 7%"? R... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:2d27f3532e4c054000b2c48a","quotes":["Although the use of last generation chemotherapy regimens has improved survi... | [
"CLM:2d27f3532e4c054000b2c48a",
"CLM:0df5d18367ac7ad0c7f831b3"
] | [
"PMCID:PMC8150287"
] | [
"SPAN:fe0735d60ee373269169b554"
] | [] | [] | {"qa_id":"QA:6e5e23205010ae128840fffd","qa_group_id":"QAG:267a6a1c9e2bed782d187a03","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"Although the use of last generation chemotherapy regimens has impr... |
QA:70a7144b8b79e3b47c66a0a4 | QAG:dae6b7155129b71cca669da4 | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "The Trastuzumab for Gastric Cancer (ToGA) study demonstrated improved overall survival (OS) with the addition of trastuzumab to chemotherapy in patients with previously untreated HER2-positive locally advanced/metastatic gastric/gastroesophageal junction cancer (GC/GEJ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:d1b34479a4fc86ef092eed94","quotes":["The Trastuzumab for Gastric Cancer (ToGA) study dem... | [
"CLM:d1b34479a4fc86ef092eed94",
"CLM:17f04cee2ef5778256edf078",
"CLM:7ed09b54db7cdf2c9858ef10"
] | [
"PMCID:PMC9813086",
"PMCID:PMC9075004"
] | [
"SPAN:a78ff7d9ac862e98905c06d6",
"SPAN:5f2f46d131f0253f25285a36"
] | [
"ASC2:9626c7142340534148f605b0"
] | [
"HYP:DCH:15f310b09cb6890ea31e6f68"
] | {"qa_id":"QA:70a7144b8b79e3b47c66a0a4","qa_group_id":"QAG:dae6b7155129b71cca669da4","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"The Trastuzumab for Gastric Cancer (ToGA) study demonstrated impro... |
QA:7969bf97215d90a053361efc | QAG:a5c19a40c441a02e4bd79590 | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "Acquisition of resistance to trastuzumab in gastric cancer cells was associated with activation of IL-6/STAT3/Jagged-1/Notch positive feedback loop"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: retur... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:36c66dde57973f4515e7f9c4","quotes":["9. Yang Z., et al. , Acquisition of resistance to trastuzumab in gastric can... | [
"CLM:36c66dde57973f4515e7f9c4",
"CLM:0df5d18367ac7ad0c7f831b3"
] | [
"PMCID:PMC10083538"
] | [
"SPAN:6bc0287da8617d4ebb2a0984"
] | [] | [] | {"qa_id":"QA:7969bf97215d90a053361efc","qa_group_id":"QAG:a5c19a40c441a02e4bd79590","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"Acquisition of resistance to trastuzumab in gastric cancer cells w... |
QA:7c81fb27392cc405bb7aa39e | QAG:35fe771f40f1af6404eb1531 | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "Patients with HER2-positive breast cancer or gastric cancer refractory to standard therapy were enrolled using a 3 + 3 design with a 21-day dose-limiting toxicity (DLT) evaluation period"? Return the original wording with paper, Claim, and Evidence Span references.
In... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:5d50a3c09d9f0837bb9e0898","quotes":["Patients with HER2-positive breast cancer or gastri... | [
"CLM:5d50a3c09d9f0837bb9e0898",
"CLM:0df5d18367ac7ad0c7f831b3",
"CLM:72fdec05b43916e51be37210",
"CLM:486fc53f92f4bf183a099282",
"CLM:49f1edbd551f98416196817e"
] | [
"PMCID:PMC9398097",
"PMCID:PMC10491560",
"PMID:37377133"
] | [
"SPAN:e3efb99988d24d03093bb010",
"SPAN:0db611bfc0e1679530fe6231",
"SPAN:a7ffaf138d98a080bde2adaf",
"SPAN:a61cb9349f7cf5bccf8174d3"
] | [
"ASC2:627743a93d78e6dd7f3d8ba3",
"ASC2:22c104957c4e5b73ce0318e0"
] | [
"HYP:DCH:66c30bbe98e0bc5f1d68ff4c"
] | {"qa_id":"QA:7c81fb27392cc405bb7aa39e","qa_group_id":"QAG:35fe771f40f1af6404eb1531","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"Patients with HER2-positive breast cancer or gastric cancer refrac... |
QA:7cdd446f870cb4d57dab77d6 | QAG:998fee14d65110a046659563 | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "FIGURE 1 Glutamine metabolism was increased in trastuzumab‐resistant HER2‐positive gastric cancer"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim, ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ecbffc692652a1b277d2b435","quotes":["FIGURE 1 Glutamine metabolism was increased in trastuzumab‐resistant HER2‐po... | [
"CLM:ecbffc692652a1b277d2b435",
"CLM:0df5d18367ac7ad0c7f831b3"
] | [
"PMCID:PMC10397568"
] | [
"SPAN:9be7f663125df7bd61e3a49e"
] | [] | [] | {"qa_id":"QA:7cdd446f870cb4d57dab77d6","qa_group_id":"QAG:998fee14d65110a046659563","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"FIGURE 1 Glutamine metabolism was increased in trastuzumab‐resista... |
QA:88b77a3872b9f40cfd344274 | QAG:dc23440de640680fd573a2c3 | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "in P2, patients with HER2+ or HER2-low (IHC 1+ or IHC 2+/ISH−) breast cancer received 3.0 or 4.0 mg/kg Q3W"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:c22c484d2e39a06ca634f6aa","quotes":["In P1, adults with HER2+ breast or gastric cancer received PF-06804103 0.15–... | [
"CLM:c22c484d2e39a06ca634f6aa",
"CLM:0df5d18367ac7ad0c7f831b3"
] | [
"PMCID:PMC10543980"
] | [
"SPAN:2e65f32876a72173903d1e6b"
] | [] | [] | {"qa_id":"QA:88b77a3872b9f40cfd344274","qa_group_id":"QAG:dc23440de640680fd573a2c3","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"in P2, patients with HER2+ or HER2-low (IHC 1+ or IHC 2+/ISH−) bre... |
QA:9033f1ebb9fa6f68918147d1 | QAG:9813c2fe1789cf95e3c9cdd0 | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "Duligotuzumab (MEHD, MEHD7945A) is a novel humanized IgG1 antibody that is directed at HER3 and EGFR, which is under investigation in phase I and II trials for metastatic colon rectal cancer and squamous cell carcinoma of the head and neck"? Return the original wording... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:722de26474c28adf9d1b0fb4","quotes":["Duligotuzumab (MEHD, MEHD7945A) is a novel humanized IgG1 antibody that is d... | [
"CLM:722de26474c28adf9d1b0fb4",
"CLM:0271f69b5949136c09787110"
] | [
"PMCID:PMC8150287"
] | [
"SPAN:7616536c86c55737549f2812"
] | [] | [] | {"qa_id":"QA:9033f1ebb9fa6f68918147d1","qa_group_id":"QAG:9813c2fe1789cf95e3c9cdd0","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"Duligotuzumab (MEHD, MEHD7945A) is a novel humanized IgG1 antibody... |
QA:91e45a8e8805899cc0ce6b63 | QAG:51e5c197117394913e4ae00d | provenance_qa | paper_evidence_availability | provenance_qa | G002 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC9719506? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC9719506","verdict":"no_released_traceable_claim","reason":"No ... | [] | [
"PMCID:PMC9719506"
] | [] | [] | [] | {"qa_id":"QA:91e45a8e8805899cc0ce6b63","qa_group_id":"QAG:51e5c197117394913e4ae00d","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G002","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC9719506... |
QA:93af38302384d2d97431ef5d | QAG:acd1c6fbc4318827b5f90962 | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "Level of HER2 gene amplification predicted response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exa... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:9e22fa55f74f75b6800cb01c","quotes":["16. Gomez-Martin C, et al. Level of HER2 gene ampli... | [
"CLM:9e22fa55f74f75b6800cb01c",
"CLM:0df5d18367ac7ad0c7f831b3",
"CLM:7e0e933702e2103e5798c4fa"
] | [
"PMCID:PMC9556512",
"PMCID:PMC9075004"
] | [
"SPAN:95b8166a5505218c05fd6d63",
"SPAN:a2203ecd2fd112549fdbcd58"
] | [
"ASC2:5b69fe1fab380012ece55cb9"
] | [
"HYP:DCH:04855fc23de8e737f3d14d87"
] | {"qa_id":"QA:93af38302384d2d97431ef5d","qa_group_id":"QAG:acd1c6fbc4318827b5f90962","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"Level of HER2 gene amplification predicted response and overall su... |
QA:985bbdc3137ace175b68ebbd | QAG:59c75262a8d7fe2cfe9a62fe | provenance_qa | paper_evidence_availability | provenance_qa | G002 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:32669315? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable an... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMID:32669315","verdict":"no_released_traceable_claim","reason":"No Cla... | [] | [
"PMID:32669315"
] | [] | [] | [] | {"qa_id":"QA:985bbdc3137ace175b68ebbd","qa_group_id":"QAG:59c75262a8d7fe2cfe9a62fe","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G002","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:32669315? E... |
QA:9ed4bd2acf6a8b273aea4429 | QAG:909cb7b4f436135104bb53b2 | provenance_qa | paper_evidence_availability | provenance_qa | G002 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC8844658? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC8844658","verdict":"no_released_traceable_claim","reason":"No ... | [] | [
"PMCID:PMC8844658"
] | [] | [] | [] | {"qa_id":"QA:9ed4bd2acf6a8b273aea4429","qa_group_id":"QAG:909cb7b4f436135104bb53b2","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G002","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC8844658... |
QA:a16d573e2dd641e8e69dd3a6 | QAG:3749c272b1fe7b4bf574bc97 | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "This review discusses pivotal clinical trial results and included current clinical trials of HER2-directed therapy in gastric cancer"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact sup... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:8195e9c2dbea74df63b56037","quotes":["Areas covered This review discusses pivotal clinical trial results and summa... | [
"CLM:8195e9c2dbea74df63b56037",
"CLM:0df5d18367ac7ad0c7f831b3"
] | [
"PMID:35034511"
] | [
"SPAN:6e154ad2d6d35fa88ed2d424"
] | [] | [] | {"qa_id":"QA:a16d573e2dd641e8e69dd3a6","qa_group_id":"QAG:3749c272b1fe7b4bf574bc97","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"This review discusses pivotal clinical trial results and included ... |
QA:a51e23e3c383893bcf594bf8 | QAG:caf4d76e087b28872c4b63ef | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "Significant progresses in the comprehension of pathogenesis of gastric cancer and a better knowledge of its biological heterogeneity have led to the identification of new targets and to the development of new molecular drugs"? Return the original wording with paper, Cl... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:4dab2fab2a071a3f78bbfb66","quotes":["Significant progresses in the comprehension of pathogenesis of gastric cance... | [
"CLM:4dab2fab2a071a3f78bbfb66",
"CLM:0df5d18367ac7ad0c7f831b3"
] | [
"PMCID:PMC8150287"
] | [
"SPAN:26928cd0cc7908cd3c6c2da4"
] | [] | [] | {"qa_id":"QA:a51e23e3c383893bcf594bf8","qa_group_id":"QAG:caf4d76e087b28872c4b63ef","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"Significant progresses in the comprehension of pathogenesis of gas... |
QA:a6297a8ef02803b3ee95c5c6 | QAG:67f23e6bc1ea5be52e294f3d | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "Patients had a median of 4 prior regimens (range, 2–8) and received a median of 1.5 (range, 1–4) prior trastuzumab-containing regimens ( Table 1 )"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:8a922db62a8a4b57a27a6849","quotes":["Patients had a median of 4 prior regimens (range, 2–8) and received a median... | [
"CLM:8a922db62a8a4b57a27a6849",
"CLM:0df5d18367ac7ad0c7f831b3"
] | [
"PMCID:PMC9398097"
] | [
"SPAN:72c793ce00781b630f4cd3d7",
"SPAN:7ccbd97cac902d20cdaf6dea"
] | [] | [] | {"qa_id":"QA:a6297a8ef02803b3ee95c5c6","qa_group_id":"QAG:67f23e6bc1ea5be52e294f3d","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"Patients had a median of 4 prior regimens (range, 2–8) and receive... |
QA:a6326c5d29d4ef869a7d2664 | QAG:9c8548484a863093f35fbe9f | provenance_qa | paper_evidence_availability | provenance_qa | G002 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:35435573? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable an... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMID:35435573","verdict":"no_released_traceable_claim","reason":"No Cla... | [] | [
"PMID:35435573"
] | [] | [] | [] | {"qa_id":"QA:a6326c5d29d4ef869a7d2664","qa_group_id":"QAG:9c8548484a863093f35fbe9f","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G002","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:35435573? E... |
QA:a76ffaf4c3dac4246d7ce80d | QAG:2eb6debb4183d88c519745b8 | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "Although adding the anti-programmed death 1 (PD-1) antibody pembrolizumab to chemotherapy did not improve efficacy in advanced HER2-negative gastric cancer 5 , there are preclinical 6-19 and clinical 20,21 rationales for adding pembrolizumab in HER2-positive disease"? ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:bfa6ad540e096316b197bb5c","quotes":["Although adding the anti-programmed death 1 (PD-1) antibody pembrolizumab to... | [
"CLM:bfa6ad540e096316b197bb5c",
"CLM:0271f69b5949136c09787110"
] | [
"PMCID:PMC8959470"
] | [
"SPAN:d719ffd276a9ca033fc1deaf"
] | [] | [] | {"qa_id":"QA:a76ffaf4c3dac4246d7ce80d","qa_group_id":"QAG:2eb6debb4183d88c519745b8","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"Although adding the anti-programmed death 1 (PD-1) antibody pembro... |
QA:a8e116952f1dbad7d021fd53 | QAG:401c5276ebbc6dc2dc67895c | provenance_qa | paper_evidence_availability | provenance_qa | G002 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:31904483? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable an... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMID:31904483","verdict":"no_released_traceable_claim","reason":"No Cla... | [] | [
"PMID:31904483"
] | [] | [] | [] | {"qa_id":"QA:a8e116952f1dbad7d021fd53","qa_group_id":"QAG:401c5276ebbc6dc2dc67895c","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G002","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:31904483? E... |
QA:ab55e4013cd6d99f19b07037 | QAG:727130fa0dcf060e537f0116 | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "Although the incidence of gastric cancer has decreased in Western Europe and the United States, it still remains a major health problem around the world"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:1903b46c4054fcbccfe4bb86","quotes":["Although the incidence of gastric cancer has decreased in Western Europe and... | [
"CLM:1903b46c4054fcbccfe4bb86",
"CLM:0271f69b5949136c09787110"
] | [
"PMCID:PMC9519153"
] | [
"SPAN:3dde3130d5f3c8f9d6bb6bca"
] | [] | [] | {"qa_id":"QA:ab55e4013cd6d99f19b07037","qa_group_id":"QAG:727130fa0dcf060e537f0116","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"Although the incidence of gastric cancer has decreased in Western ... |
QA:ad722f099383b96fbb40a378 | QAG:4f520c9eccc281cc45198e5c | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "In this study, we found that increased glutamine metabolism promotes trastuzumab resistance in HER2‐positive gastric cancer, which promoted M2 macrophage polarization and angiogenesis through GLS1 microvesicles"? Return the original wording with paper, Claim, and Evide... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:e1b9decb9515ceb58b22bc70","quotes":["4. In this study, we found that increased glutamine metabolism promotes tras... | [
"CLM:e1b9decb9515ceb58b22bc70",
"CLM:0df5d18367ac7ad0c7f831b3"
] | [
"PMCID:PMC10397568"
] | [
"SPAN:457936dfbbc01d1ad0cba79b"
] | [] | [] | {"qa_id":"QA:ad722f099383b96fbb40a378","qa_group_id":"QAG:4f520c9eccc281cc45198e5c","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"In this study, we found that increased glutamine metabolism promot... |
QA:afe58a799916baf095453bce | QAG:9434f188c4348d306f0518a2 | provenance_qa | paper_evidence_availability | provenance_qa | G002 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:34657203? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable an... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMID:34657203","verdict":"no_released_traceable_claim","reason":"No Cla... | [] | [
"PMID:34657203"
] | [] | [] | [] | {"qa_id":"QA:afe58a799916baf095453bce","qa_group_id":"QAG:9434f188c4348d306f0518a2","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G002","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:34657203? E... |
QA:b26fb50b2789f509bb04d2bb | QAG:04c60f05f741f667cda79c69 | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "When we used trastuzumab to treat tumor tissues containing trastuzumab‐sensitive HER2‐positive gastric cancer cells (labeled “TS + Tra”), both angiogenesis and the number of tumor cells decreased significantly compared to those in the control group"? Return the origina... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:9035917466ba622321f040b9","quotes":["When we used trastuzumab to treat tumor tissues containing trastuzumab‐sensi... | [
"CLM:9035917466ba622321f040b9",
"CLM:0df5d18367ac7ad0c7f831b3"
] | [
"PMCID:PMC10397568"
] | [
"SPAN:6de38d83f7b3307820026255"
] | [] | [] | {"qa_id":"QA:b26fb50b2789f509bb04d2bb","qa_group_id":"QAG:04c60f05f741f667cda79c69","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"When we used trastuzumab to treat tumor tissues containing trastuz... |
QA:b3c1a122d91186fc956a9a67 | QAG:2fd61ffc7a3aefbc27343643 | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "4 , 5 , 6 , 7 , 8 Trastuzumab for Gastric Cancer (ToGA) trial showed that trastuzumab in combination with chemotherapy led to a longer overall survival (OS, 13.8 months vs. 11.1 months) and progression‐free survival (PFS, 6.7 months vs. 5.5 months) compared with cispla... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:de77e3eff568bfe708ff8f15","quotes":["4 , 5 , 6 , 7 , 8 Trastuzumab for Gastric Cancer (ToGA) trial showed that tr... | [
"CLM:de77e3eff568bfe708ff8f15",
"CLM:0df5d18367ac7ad0c7f831b3"
] | [
"PMCID:PMC9972160"
] | [
"SPAN:ea8ce1c8e05ad4f8c42034fb"
] | [] | [] | {"qa_id":"QA:b3c1a122d91186fc956a9a67","qa_group_id":"QAG:2fd61ffc7a3aefbc27343643","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"4 , 5 , 6 , 7 , 8 Trastuzumab for Gastric Cancer (ToGA) trial show... |
QA:b878181492e1bb02977bec71 | QAG:c1c02a9403e528a83ddad2b7 | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "In this study, we found that increased glutamine metabolism promotes trastuzumab resistance in HER2‐positive gastric cancer, which promoted M2 macrophage polarization and angiogenesis through GLS1 microvesicles"? Return the original wording with paper, Claim, and Evide... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:353ee387dc0c7fed5d59e3eb","quotes":["4. In this study, we found that increased glutamine... | [
"CLM:353ee387dc0c7fed5d59e3eb",
"CLM:0df5d18367ac7ad0c7f831b3",
"CLM:29b27485750fba0528103531"
] | [
"PMCID:PMC10397568",
"PMCID:PMC10101806"
] | [
"SPAN:457936dfbbc01d1ad0cba79b",
"SPAN:7dc91ac2bf94be3d2447ae6b"
] | [
"ASC2:2d130925885e4cefadb6387c"
] | [
"HYP:DCH:6fe71085b1883f30b48a81c1"
] | {"qa_id":"QA:b878181492e1bb02977bec71","qa_group_id":"QAG:c1c02a9403e528a83ddad2b7","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"In this study, we found that increased glutamine metabolism promot... |
QA:bf545e4ff0b213d8ecefdc04 | QAG:e3b35e2f114a9b99b754bc58 | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "A total of 587 patients were enrolled of whom 528 were breast or gastric cancer and the remaining 59 were other solid cancers"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:bf317aff58ad2af661a09a9b","quotes":["A total of 587 patients were enrolled, of whom 528 were breast or gastric ca... | [
"CLM:bf317aff58ad2af661a09a9b",
"CLM:0271f69b5949136c09787110"
] | [
"PMCID:PMC9414434"
] | [
"SPAN:81991c69c0425234cd81c5be"
] | [] | [] | {"qa_id":"QA:bf545e4ff0b213d8ecefdc04","qa_group_id":"QAG:e3b35e2f114a9b99b754bc58","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"A total of 587 patients were enrolled of whom 528 were breast or g... |
QA:bf7f8790070b52a0a38fdb67 | QAG:68e7451a4525bac4e7c9bead | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "There was a lack of effective and durable treatments for patients with HER2+ metastatic gastric cancer who had received a prior trastuzumab-based regimen before 2020. Patients incurred substantial financial burden after progression on or after first-line trastuzumab"? ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:a814d7cfb1ed00b09aec65de","quotes":["There was a lack of effective and durable treatments for patients with HER2+... | [
"CLM:a814d7cfb1ed00b09aec65de",
"CLM:0df5d18367ac7ad0c7f831b3"
] | [
"PMCID:PMC10491560"
] | [
"SPAN:2ffa787d02465f767e9f5120"
] | [] | [] | {"qa_id":"QA:bf7f8790070b52a0a38fdb67","qa_group_id":"QAG:68e7451a4525bac4e7c9bead","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"There was a lack of effective and durable treatments for patients ... |
QA:c0c7a0fa202baeb547b8024d | QAG:34ce172619ab6750c5f5a1e8 | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "Trastuzumab, the only HER2-targeted agent used as a standard first-line treatment for advanced HER2-positive gastric cancer, has achieved a breakthrough in this patient population ( 1 )"? Return the original wording with paper, Claim, and Evidence Span references.
Int... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:2117bab5d89c921d5d76db93","quotes":["Trastuzumab, the only HER2-targeted agent used as a... | [
"CLM:2117bab5d89c921d5d76db93",
"CLM:0df5d18367ac7ad0c7f831b3",
"CLM:26f81762001cee59569403eb",
"CLM:52ce793834680a7e9a0f558c"
] | [
"PMCID:PMC9662874",
"PMID:32469182",
"PMCID:PMC9427959"
] | [
"SPAN:a66c620f797193955a04eeb1",
"SPAN:801028bc0dc42eeac2d8d70a",
"SPAN:894c660b4595cfc94de82aa3"
] | [
"ASC2:4cdc5bcefc6b05cf4b4e7c91",
"ASC2:a505694fcc9d33b2ce05c813"
] | [
"HYP:DCH:1a1c890e60fae8ec7e84b530"
] | {"qa_id":"QA:c0c7a0fa202baeb547b8024d","qa_group_id":"QAG:34ce172619ab6750c5f5a1e8","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"Trastuzumab, the only HER2-targeted agent used as a standard first... |
QA:c3e4056cbe31c8ba40a303ed | QAG:48d6389d11ab0b9240148c2d | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "A retrospective analysis for patients with HER2-positive gastric cancer who received trastuzumab-based chemotherapy: in the perspectives of ethnicity and histology"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance req... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:8a761323f291c5d518132388","quotes":["6. Yi JH, et al. A retrospective analysis for patie... | [
"CLM:8a761323f291c5d518132388",
"CLM:0df5d18367ac7ad0c7f831b3",
"CLM:7ed09b54db7cdf2c9858ef10"
] | [
"PMCID:PMC10730520",
"PMCID:PMC9075004"
] | [
"SPAN:7e124c040720954c924c584d",
"SPAN:5f2f46d131f0253f25285a36"
] | [
"ASC2:b6106dfc6d986cf75c00aa2a"
] | [
"HYP:DCH:50d6e0f3c8a8e03f41ce3b39"
] | {"qa_id":"QA:c3e4056cbe31c8ba40a303ed","qa_group_id":"QAG:48d6389d11ab0b9240148c2d","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"A retrospective analysis for patients with HER2-positive gastric c... |
QA:c4de7b4e7b88e1778ae5bd61 | QAG:04fd45272d897c351d32d86a | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "gov/drugs/resources-information-approved-drugs/fda-grants promoted approval-pembrolizumab-advanced-gastric-cancer#:~:text=On%20September%2022%2C%202017%2C%20the,by%20an%20FDA%2Dapproved%20test"? Return the original wording with paper, Claim, and Evidence Span reference... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ed48dbfa748e5fe9af833ea9","quotes":["FDA grants accelerated approval to pembrolizumab for advanced gastric cancer... | [
"CLM:ed48dbfa748e5fe9af833ea9",
"CLM:0271f69b5949136c09787110"
] | [
"PMCID:PMC10491560"
] | [
"SPAN:0b0856ece80c2662a828891d"
] | [] | [] | {"qa_id":"QA:c4de7b4e7b88e1778ae5bd61","qa_group_id":"QAG:04fd45272d897c351d32d86a","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"gov/drugs/resources-information-approved-drugs/fda-grants promoted... |
QA:ca1f63d10c296a521cd858d5 | QAG:9781c0446d54117462723378 | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "FIGURE 3 RC48-ADC decreased the phosphorylation of human epidermal growth factor receptor 2 (HER2) and induced cell cycle arrest in G2/M phase and apoptosis in gastric cancer (GC) patient-derived xenograft (PDX) models"? Return the original wording with paper, Claim, a... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:5fb410e75883da00a639458d","quotes":["FIGURE 3 RC48-ADC decreased the phosphorylation of human epidermal growth fa... | [
"CLM:5fb410e75883da00a639458d",
"CLM:0271f69b5949136c09787110"
] | [
"PMCID:PMC8769204"
] | [
"SPAN:a4ab1af054d6136efcbeed85"
] | [] | [] | {"qa_id":"QA:ca1f63d10c296a521cd858d5","qa_group_id":"QAG:9781c0446d54117462723378","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"FIGURE 3 RC48-ADC decreased the phosphorylation of human epidermal... |
QA:cc8b8d366962dbb68b756905 | QAG:ea6cd4f776693ac9c0023f7b | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "Using population pharmacokinetic and exposure-response (efficacy/safety) models, exposure-efficacy data from 117 patients and exposure-safety data from 158 patients in Japan who received T-DXd 6.4 mg/kg as second-line or later treatment were bridged to RWE including co... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:49f1edbd551f98416196817e","quotes":["Using population pharmacokinetic and exposure-respo... | [
"CLM:49f1edbd551f98416196817e",
"CLM:0271f69b5949136c09787110",
"CLM:5d50a3c09d9f0837bb9e0898"
] | [
"PMID:37377133",
"PMCID:PMC9398097"
] | [
"SPAN:a61cb9349f7cf5bccf8174d3",
"SPAN:e3efb99988d24d03093bb010"
] | [
"ASC2:22c104957c4e5b73ce0318e0"
] | [
"HYP:DCH:e34b67fbc1a970022bcf4b5d"
] | {"qa_id":"QA:cc8b8d366962dbb68b756905","qa_group_id":"QAG:ea6cd4f776693ac9c0023f7b","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"Using population pharmacokinetic and exposure-response (efficacy/s... |
QA:cd2b8b006d08df199b28f232 | QAG:201aa19aef515c65e5c4f8f9 | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "whereas patients with gastric cancer were required to have previously received a trastuzumab-containing chemotherapy regimen"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:486fc53f92f4bf183a099282","quotes":["HER2-positive disease was documented as fluorescenc... | [
"CLM:486fc53f92f4bf183a099282",
"CLM:0df5d18367ac7ad0c7f831b3",
"CLM:72fdec05b43916e51be37210"
] | [
"PMCID:PMC9398097",
"PMCID:PMC10491560"
] | [
"SPAN:a7ffaf138d98a080bde2adaf",
"SPAN:0db611bfc0e1679530fe6231"
] | [
"ASC2:627743a93d78e6dd7f3d8ba3"
] | [
"HYP:DCH:4ffba0b594e66014ed4ef4b9"
] | {"qa_id":"QA:cd2b8b006d08df199b28f232","qa_group_id":"QAG:201aa19aef515c65e5c4f8f9","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"whereas patients with gastric cancer were required to have previou... |
QA:cfe5b0763747f1302db6bfc6 | QAG:78498f879f368211ca4686e6 | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "Although addition of trastuzumab to chemotherapy in the 1L setting has shown a survival benefit over chemotherapy alone , trastuzumab continuation beyond progression in advanced gastric cancer has failed to meet clinical benefit in patients with HER2+ mGC in clinical t... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:b10df73bac2011a949454392","quotes":["Although addition of trastuzumab to chemotherapy in the 1L setting has shown... | [
"CLM:b10df73bac2011a949454392",
"CLM:0df5d18367ac7ad0c7f831b3"
] | [
"PMCID:PMC10491560"
] | [
"SPAN:ecaf65442706da3dfdcbe33b"
] | [] | [] | {"qa_id":"QA:cfe5b0763747f1302db6bfc6","qa_group_id":"QAG:78498f879f368211ca4686e6","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"Although addition of trastuzumab to chemotherapy in the 1L setting... |
QA:db1cb38ee46df7e6fcc40204 | QAG:c0d55ddef38b6343b8ebca65 | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "Conclusion With only 16 patients enrolled, the present study has very low power to detect any clinical benefit of trastuzumab plus irinotecan beyond disease progression in patients with HER2-positive advanced gastric cancer who previously received trastuzumab"? Return ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:7ed09b54db7cdf2c9858ef10","quotes":["Conclusion With only 16 patients enrolled, the present study has very low po... | [
"CLM:7ed09b54db7cdf2c9858ef10",
"CLM:0df5d18367ac7ad0c7f831b3"
] | [
"PMCID:PMC9075004"
] | [
"SPAN:5f2f46d131f0253f25285a36"
] | [] | [] | {"qa_id":"QA:db1cb38ee46df7e6fcc40204","qa_group_id":"QAG:c0d55ddef38b6343b8ebca65","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"Conclusion With only 16 patients enrolled, the present study has v... |
QA:dbbd40a94563d0fcad99e839 | QAG:0bbb2fd803c6a95f11a4e5a5 | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "Methods From among a total of 199 patients who received T-mab-based chemotherapy for stage IV HER2-positive gastric or gastroesophageal junction cancer between 2011 and 2018, the subjects of this retrospective analysis were 20 patients who subsequently underwent radica... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:94d6742a6b21944e4b2934aa","quotes":["Methods From among a total of 199 patients who rece... | [
"CLM:94d6742a6b21944e4b2934aa",
"CLM:0271f69b5949136c09787110",
"CLM:5d50a3c09d9f0837bb9e0898"
] | [
"PMID:32451714",
"PMCID:PMC9398097"
] | [
"SPAN:16256df8d64928c0d4978b6a",
"SPAN:e3efb99988d24d03093bb010"
] | [
"ASC2:fa92c823dc0c29a5a5d388a1"
] | [
"HYP:DCH:4989f7420133a70097cab30c"
] | {"qa_id":"QA:dbbd40a94563d0fcad99e839","qa_group_id":"QAG:0bbb2fd803c6a95f11a4e5a5","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"Methods From among a total of 199 patients who received T-mab-base... |
QA:dedfa4101aba5303d83fee7e | QAG:ef0b288c35d87a80d5291403 | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "They also showed that DXd increased the expression of MHC class I in murine CRC cells in vitro, suggesting that T-DXd could directly trigger the expression of MHC class I in HER2-positive cancer cells"? Return the original wording with paper, Claim, and Evidence Span r... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:708e1e03946cb4b9438c15d0","quotes":["They also showed that DXd increased the expression of MHC class I in murine ... | [
"CLM:708e1e03946cb4b9438c15d0",
"CLM:0271f69b5949136c09787110"
] | [
"PMCID:PMC8376901"
] | [
"SPAN:dde5536e810a9cf2484164fe"
] | [] | [] | {"qa_id":"QA:dedfa4101aba5303d83fee7e","qa_group_id":"QAG:ef0b288c35d87a80d5291403","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"They also showed that DXd increased the expression of MHC class I ... |
QA:e3220e272ace4cbbdd916f15 | QAG:4b4e05ce890fdb9003213d4c | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "Due to incomplete accrual, the present study has very low power to detect any clinical benefit of trastuzumab and irinotecan beyond disease progression in patients with HER2-positive metastatic or advanced gastric cancer who previously received trastuzumab due to the l... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:7e0e933702e2103e5798c4fa","quotes":["Due to incomplete accrual, the present study has ve... | [
"CLM:7e0e933702e2103e5798c4fa",
"CLM:0df5d18367ac7ad0c7f831b3",
"CLM:5d1b30abe9b70b562ab63e93"
] | [
"PMCID:PMC9075004",
"PMCID:PMC10101806"
] | [
"SPAN:a2203ecd2fd112549fdbcd58",
"SPAN:64aba72ce3b62600b2dd45b3"
] | [
"ASC2:1734873937def967dc6b5671"
] | [] | {"qa_id":"QA:e3220e272ace4cbbdd916f15","qa_group_id":"QAG:4b4e05ce890fdb9003213d4c","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"Due to incomplete accrual, the present study has very low power to... |
QA:e795a663611269bdac0a48ae | QAG:e59695bb972d49842c3cac1c | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "To verify the results of the cell experiments, we collected HER2‐positive gastric cancer tissues from trastuzumab‐sensitive and trastuzumab‐resistant patients for transcriptome sequencing and found that amino acid metabolism scores increased in trastuzumab‐resistant pa... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:f4bf1f5934066afce932efae","quotes":["To verify the results of the cell experiments, we collected HER2‐positive ga... | [
"CLM:f4bf1f5934066afce932efae",
"CLM:0df5d18367ac7ad0c7f831b3"
] | [
"PMCID:PMC10397568"
] | [
"SPAN:6d366f65f3e8af6422097c64"
] | [] | [] | {"qa_id":"QA:e795a663611269bdac0a48ae","qa_group_id":"QAG:e59695bb972d49842c3cac1c","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"To verify the results of the cell experiments, we collected HER2‐p... |
QA:e87be156bc6900cd99ffbb68 | QAG:806d3e76743427ef6d4b6839 | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "An objective response was reported in 51% of the patients in the trastuzumab deruxtecan group, as compared with 14% of those in the physician's choice group (P Conclusions Therapy with trastuzumab deruxtecan led to significant improvements in response and overall survi... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:26f81762001cee59569403eb","quotes":["An objective response was reported in 51% of the pa... | [
"CLM:26f81762001cee59569403eb",
"CLM:0df5d18367ac7ad0c7f831b3",
"CLM:52ce793834680a7e9a0f558c"
] | [
"PMID:32469182",
"PMCID:PMC9427959"
] | [
"SPAN:801028bc0dc42eeac2d8d70a",
"SPAN:894c660b4595cfc94de82aa3"
] | [
"ASC2:a505694fcc9d33b2ce05c813"
] | [
"HYP:DCH:7875e3c875300cc24a4a93e3"
] | {"qa_id":"QA:e87be156bc6900cd99ffbb68","qa_group_id":"QAG:806d3e76743427ef6d4b6839","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"An objective response was reported in 51% of the patients in the t... |
QA:eaf99b206d2ae416410d04d8 | QAG:3139ad49aa9301815edb81f8 | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "In this study, data from patients with HER2- positive advanced gastric cancer who received trastuzumab deruxtecan (T-DXd) were analyzed"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:f345e98440bc539b7a780663","quotes":["In this study, data from patients with HER2- positive advanced gastric cance... | [
"CLM:f345e98440bc539b7a780663",
"CLM:17f04cee2ef5778256edf078"
] | [
"PMCID:PMC9030612"
] | [
"SPAN:70d45051e4687d183b988a9e"
] | [] | [] | {"qa_id":"QA:eaf99b206d2ae416410d04d8","qa_group_id":"QAG:3139ad49aa9301815edb81f8","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"In this study, data from patients with HER2- positive advanced gas... |
QA:eb1d30cd9f153a0b12899436 | QAG:9fecc9a903bb6a77ee0e92da | provenance_qa | exact_evidence_retrieval | provenance_qa | G002 | en | train | Which exact source passage supports the statement "In this study, we aims to evaluate the efficacy and safety of trastuzumab in combination with chemotherapy in HER2 -positive metastatic colorectal cancer (mCRC)"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requir... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:29b27485750fba0528103531","quotes":["In this study, we aimed to assess the efficacy and safety of trastuzumab in ... | [
"CLM:29b27485750fba0528103531",
"CLM:1903b46c4054fcbccfe4bb86"
] | [
"PMCID:PMC10101806"
] | [
"SPAN:7dc91ac2bf94be3d2447ae6b"
] | [] | [] | {"qa_id":"QA:eb1d30cd9f153a0b12899436","qa_group_id":"QAG:9fecc9a903bb6a77ee0e92da","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G002","question":"Which exact source passage supports the statement \"In this study, we aims to evaluate the efficacy and safety of tras... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.